ClonoSEQ MRD negativity at day 90 is a strong predictor for progression-free and overall survival after BCMA-directed CAR T-cell therapy for relapsed multiple myeloma.
Retrospective analysis shows MRD negativity improves progression-free survival and overall survival in relapsed multiple myeloma after BCMA CAR T-cell therapy.
Key Points
Evaluate the impact of minimal residual disease negativity at day 90 on survival outcomes after CAR T-cell therapy in multiple myeloma.
Retrospective analysis of 171 multiple myeloma patients treated with BCMA CAR T-cell therapy.
Utilized NGS-based testing to assess minimal residual disease at day 90 post-treatment.
Survival outcomes measured using the Kaplan-Meier method and analyzed with log-rank tests and Cox regression.
MRD negativity at day 90 predicted longer progression-free survival (20 months vs. 11 months).
Overall survival was also improved in MRD-negative patients (38 months vs. 26 months).
Significant differences in response rates were observed, with MRD-negative patients showing a higher overall response rate (98% vs. 68%).
Cite This Study
Grajales‐Cruz et al. (2025) studied this question.